|Articles|March 17, 2015
Encouraging Results from Imbruvica in CLL and Small Lymphocytic Lymphoma
Improved survival without disease progression prompted independent reviewers to unblind the study comparing Imbruvica against a placebo, in combination with bendamustine and rituximab.
Advertisement
An independent panel recommended unblinding a late-stage study testing Pharmacyclics Inc and Johnson & Johnson's Imbruvica, after the treatment was successful against two similar forms of cancer in combination with other drugs.
Pharmacyclics, which recently agreed to be acquired by AbbVie Inc for about $21 billion, said Imbruvica showed a statistically significant improvement in survival without disease progression, the study's main goal.
Imbruvica, which is co-marketed by Pharmacyclics and J&J, is already approved for four cancer indications in the United States.
Link to the Reuters report:
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Use of Collaborative Care Grows Rapidly, Uneven Medicaid Coverage Drives State Gaps
2
Senate Democrats Outline Drug Pricing Agenda to Cut Patient Costs
3
Intraarterial Alteplase After Thrombectomy May Improve Stroke Recovery: CHOICE2
4
Stroke Rates Are Rising in Younger Adults, as Older Populations See Declines: Emily R. Fisher, MD
5
